Navigation Links
Regado Biosciences, Inc. to Present at the BIO-Europe Spring® 2012 Conference in Amsterdam, The Netherlands
Date:3/14/2012

BASKING RIDGE, N.J., March 14, 2012 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the BIO-Europe Spring® 2012 conference at 9:15 a.m. local time (3:15 a.m. EDT) on March 21, 2012 at the Amsterdam RAI Convention Center in Amsterdam, The Netherlands.

The presentation will include an overview of the Company's pipeline with emphasis on the lead development program, the innovative anticoagulant system REG1, including a summary of the groundbreaking results of the REG1 phase 2b trial (RADAR).  Additionally, a summary of the positive results of the FDA end-of-phase 2 meeting and a description of the resulting phase 3 development program and timeline, minimized for cost and maximized for probability of success, will be provided.

ABOUT REGADO BIOSCIENCES
Regado Biosciences, Inc. is a private biopharmaceutical company pioneering a new therapeutic technology with the creation and development of proprietary controllable aptamer drug systems.  Each system comprises a nuclease-stabilized RNA aptamer, the therapeutic effect of which can be reversed partially or completely in real time by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market in need of drugs with improved safety profiles and a greater degree of therapeutic control.  The products in Regado's pipeline are designed to act as optimized antithrombotics, uniquely and concomitantly minimizing the risk of ischemia and bleeding, and, by allowing patient specific tuning of the desired therapeutic effect, provide a safe and unique approach to personalized medicine.

'/>"/>
SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH
2. Regado Biosciences, Inc. to Present at the Sofinnova Japan Biopharma Partnering Conference in Tokyo, Japan
3. Regado Biosciences to Present at the Annual UBS Global Life Sciences Conference in New York City
4. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
5. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
6. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
7. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
8. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
9. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
10. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
11. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 ResMed (NYSE: ... infringement action against Chinese medical device manufacturer BMC Medical Co., ... today that BMC,s masks listed below infringe ResMed,s patents, and ... these masks in the United States : ... nasal mask , Willow nasal pillows mask , ...
(Date:12/24/2014)... 23, 2014  Lockton Dunning Benefits, the ... announced the addition of Vice President Kim ... Dunning,s Pharmacy Consulting team, Excelsior Solutions. ... experience to the position.  Most recently, she worked ... Diplomat Specialty Pharmacy, where she has held various ...
(Date:12/24/2014)... and RALEIGH, N.C. , Dec. ... Endo International plc (NASDAQ: ENDP ) (TSX: ... BDSI ) announced today that they have submitted a ... to the U.S. Food and Drug Administration (FDA).  Buprenorphine ... of pain severe enough to require daily, around-the-clock, long-term ...
Breaking Medicine Technology:ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2Kim Foerster Joins Lockton Companies 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
(Date:12/26/2014)... is said that nothing makes a lady feel more feminine ... supplier, shows its new selection of navy cocktail dresses ... UWDress.com’s navy cocktail gowns are the cornerstones of the site’s ... Simple dresses in bright neon colors can be dressed up ... for those who want to shine among the crowd by ...
(Date:12/26/2014)... Plugin and template developers from Pixel Film Studios ... Cut Pro X. , “TransPack Volume 5 gives users the ... an industry professional look” Said Christina Austin, CEO of Pixel ... 5, a new level of professionalism will become the standard.” ... Final Cut Pro X transitions featuring organic animations. Choose from ...
(Date:12/26/2014)... (DaWei Induction Heating Co.) is a comprehensive high-tech business ... of a series of induction heating equipment. Today, the ... induction brazing equipments . , According to a ... refers to the joining of two or more components ... says that there are fundamental differences in the two ...
(Date:12/25/2014)... The click strand woven ... and durability. Today, the business announces a click ... until Jan. 30, 2015. , Click strand woven ... BambooFlooringChina.com is a well-known brand in the bamboo ... find a reliable bamboo flooring supplier. , “We ...
(Date:12/25/2014)... “Every three months the trends for ... evening dress will be one of the hottest styles in ... says. Today, the company releases 26 A-line sweetheart evening dresses, ... off. , “We are trying our best to help ... latest designs. Along with affordable prices, we provide discounted delivery ...
Breaking Medicine News(10 mins):Health News:UWDress.com Shows Its New Navy Cocktail Dresses For 2015 2Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2
... clinics and hospitals in the United States as the International Brain ... the condition. Researchers believe that the quality and type of care ... , ... Denver, CO (PRWEB) August 26, 2008 -- ...
... (NASDAQ: QLTI;,TSX: QLT) announced today that QLT USA, ... license agreement with Reckitt Benckiser,Pharmaceuticals Inc. for its ... being retained by QLT USA and its,prior licensees. ... related asset,purchase agreement, QLT USA received an aggregate ...
... Susan G. Komen for the Cure(R), the,leader of ... organization,the Susan G. Komen for the Cure Advocacy ... about breast self awareness and the need for,increased ... and,underinsured., (Logo: http://www.newscom.com/cgi-bin/prnh/20070122/NYM084LOGO ), Komen ...
... -- Mindray,Medical International Limited (NYSE: MR ), ... in China, today released select historical,financial figures converted ... announced in May, 2008, Mindray changed its reporting ... effective April 1, 2008.,Accordingly, Mindray has issued these ...
... ATRC ), a medical device company and a ... will present at the following,investor conferences during September:, ... Four Seasons,Hotel in Boston on Wednesday, September 3, 2008. ... to present at 10:55,a.m. Eastern time., -- The ...
... docs to effectiveness of alternative therapies , , MONDAY, Aug. ... of antipsychotic drugs in seniors with dementia. But the ... a finding which suggests that warnings may not be ... Between late 2002 and June 2005, Health Canada issued ...
Cached Medicine News:Health News:LegalView Highlights Top Brain Injury Rehabilitation Hospitals in the United States - 5.3 Million Americans Suffer from TBI 2Health News:LegalView Highlights Top Brain Injury Rehabilitation Hospitals in the United States - 5.3 Million Americans Suffer from TBI 3Health News:LegalView Highlights Top Brain Injury Rehabilitation Hospitals in the United States - 5.3 Million Americans Suffer from TBI 4Health News:QLT announces agreement to exclusively license the Atrigel(R) Technology to Reckitt Benckiser Pharmaceuticals Inc. 2Health News:QLT announces agreement to exclusively license the Atrigel(R) Technology to Reckitt Benckiser Pharmaceuticals Inc. 3Health News:Komen Travels to Democratic Convention in Denver to Raise Awareness of Breast Cancer Issues 2Health News:Mindray Releases Historical Financial Results Converted into US Dollar Terms 2Health News:AtriCure to Participate at the Thomas Weisel Partners Healthcare Conference and the UBS Global Life Sciences Conference in September 2Health News:Antipsychotic Drug Use Up in Elderly Despite Warnings 2
Lacrimal Cannulas, 19 g. shaft tapering to 23 g. cannula, straight. Overall length 37.5 mm. 5/box....
Anterior Chamber Needle, 21 g., 8 mm from bend to tip. Overall length 25 mm. 5/box....
Nucleus Hydrodissection Cannula, 25 g. Angled with flattened tip. 7 mm angled shaft with flattened tip for insertion under the capsular flap. Overall length 19 mm. 5/box....
Posterior Capsule Polisher, 21 g. Roughened tip, top port. Overall length 23 mm. 5/box....
Medicine Products: